During the past decade, Papageorgiou General Hospital of Thessaloniki conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 19 clinical trials were completed, i.e. on average, 44.2% percent of trials that started reached the finish line to date. In the past 5 years, 26 clinical trials started and 15 clinical trials were completed. i.e. 57.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Papageorgiou General Hospital of Thessaloniki" #1 sponsor was "Aristotle University Of Thessaloniki" with 6 trials, followed by "Bayer" with 6 trials sponsored, "Eli Lilly and Company" with 5 trials sponsored, "Janssen Research & Development, LLC" with 5 trials sponsored and "Papageorgiou General Hospital" with 5 trials sponsored. Other sponsors include 39 different institutions and companies that sponsored additional 37 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Papageorgiou General Hospital of Thessaloniki" #1 collaborator was "Bristol-Myers Squibb" with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator, "Agia Sofia Children's Hospital, Athens, Greece" with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 25 different institutions and companies that were collaborators in the rest 35 trials.

According to Clinical.Site data, the most researched conditions in "Papageorgiou General Hospital of Thessaloniki" are "Retinopathy of Prematurity" (4 trials), "Prostate Cancer" (3 trials), "Renal Cell Carcinoma" (3 trials), "Breast Cancer" (2 trials) and "Osteoporosis" (2 trials). Many other conditions were trialed in "Papageorgiou General Hospital of Thessaloniki" in a lesser frequency.

Most popular intervention types in "Papageorgiou General Hospital of Thessaloniki" are "Drug" (50 trials), "Biological" (5 trials), "Device" (5 trials), "Other" (5 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Gemcitabine" (4 trials), "Carboplatin" (3 trials), "Tirzepatide" (3 trials) and "Abemaciclib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Papageorgiou General Hospital of Thessaloniki" are 65 trials for "All" genders, 3 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Papageorgiou General Hospital of Thessaloniki". undefined are not yet recruiting, 13 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 39 completed trials in Papageorgiou General Hospital of Thessaloniki, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Papageorgiou General Hospital of Thessaloniki, 0 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 11 trials, and there were also 2 trials that are defined as “Not Applicable".